Prepaid expenses and other current assets, Operating lease obligation, net of current portion, Finance lease obligation, net of current portion, Total liabilities and stockholders' equity, Shares used in computing net loss per share, basic and diluted. These strong results are a testament to our unique combination of comprehensive menu, durable customer relationships and ability to execute," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. The company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in the Detect Lysosomal Disorders program in January 2020. Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. This compares to loss of $0.69 per share a year ago. Changes in operating assets and liabilities, net of businesses acquired: Proceeds from sales of marketable securities, Proceeds from maturities of marketable securities, Acquisition of businesses, net of cash acquired, Net cash provided by (used in) investing activities, Proceeds from public offerings of common stock, net of issuance costs, Proceeds from issuance of common stock, net, Proceeds from issuance of convertible senior notes, net, Net cash provided by financing activities, Net increase (decrease) in cash, cash equivalents and restricted cash, Cash, cash equivalents and restricted cash at beginning of period, Cash, cash equivalents and restricted cash at end of period, Reconciliation of GAAP to Non-GAAP Cost of Revenue, Amortization of acquired intangible assets, Reconciliation of GAAP to Non-GAAP Research and Development Expense, Acquisition-related stock-based compensation, Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense, Reconciliation of GAAP to Non-GAAP General and Administrative Expense, Acquisition-related post-combination expense, Reconciliation of Operating Expense to Non-GAAP Operating Expense, Reconciliation of Net Loss to Non-GAAP Net Loss Per Share, Non-GAAP net loss per share, basic and diluted, Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn, Proceeds from public offering of common stock, net of issuance costs. Email: ir@invitae.com, -- Increased annual revenue by approximately 47% and annual volume by nearly 60% year-over-year --. We will release your report to your physician as soon as it is available. "We further advanced clinical understanding of the importance of genetic information with the publication of several studies, including a collaboration supporting universal testing for cancer patients. Track order status in real time and keep a record of previous orders. Will Invitae ever release results directly to my patient? http://www.directeventreg.com/registration/event/7916067, http://www.prnewswire.com/news-releases/invitae-reports-68-7-million-in-revenue-driven-by-170-000-samples-accessioned-in-the-third-quarter-of-2020--301167447.html, Accessioned approximately 170,000 samples in the third quarter of 2020 compared to 129,000 samples in the third quarter of 2019. Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020. • Cash burn for the three months ended March 31, 2020 includes $32.3 million of cash paid in connection with the acquisition of Diploid and cash burn for the three months ended June 30, 2020 includes $25.4 million of cash paid in connection with the acquisitions of Genelex and YouScript. Cash burn was $64.9 million for the quarter. Launched Invitae Discover, a clinical research platform that leverages biometric data available through Apple Watch to provide better understanding of the genetic causes of disease, with the first study in cardiovascular disease. Non-GAAP net loss was $81.7 million, or $0.62 non-GAAP net loss per share, in the third quarter of 2020. Cash burn, including various financing and acquisition-related expenses, was $278.3 million in 2019, including $75.5 million in the fourth quarter. A replay of the webcast and conference call will be available shortly after the conclusion of the call and will be archived on the company's website. Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100.
All rights reserved. Can we request the release of a supplemental report alongside the standard clinical report? SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. Non-GAAP operating expense, which excludes amortization of acquired intangible assets and acquisition-related stock-based compensation and post-combination expense, was $293.6 million for the full year 2019 compared to $185.1 million in 2018, and $89.2 million in the fourth quarter of 2019. With both centralized and distributed capabilities, Invitae is now uniquely positioned to provide flexibility in meeting customers' needs. Invitae Reports 47% Growth in Quarterly Revenue and Volume Year-Over-Year May 07, 2019 On track to deliver more than 500,000 test samples and more than $220 million in revenue in 2019 Signed eight new biopharma partnerships in the quarter, expanding the breadth of the genome network Net increase in cash, cash equivalents and restricted cash was $39.4 million in 2019 and $315.6 million for the fourth quarter. My patient has a positive result in TP53 and it says that they may qualify for the TP53 variant program. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. All rights reserved. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. Online registration: http://www.directeventreg.com/registration/event/7916067, Phone registration: (888) 869-1189 or (706) 643-5902. Total operating expense, excluding cost of revenue, for the third quarter of 2020 was $102.9 million. Net decrease in cash, cash equivalents and restricted cash for the quarter was $61.4 million. Sign up to receive Invitae financial information by email. “Invitae is a leader in medical genetic testing and has driven innovation in this area for more than a decade. Management is excluding from some or all of its non-GAAP operating results (1) amortization of acquired intangible assets, (2) acquisition-related stock-based compensation related to inducement grants, (3) post-combination expense related to the acceleration of equity grants in connection with business combinations, and (4) acquisition-related income tax benefits. Find the latest Earnings Report Date for Invitae Corporation Common Stock (NVTA) at Nasdaq.com. Non-GAAP operating expense was $102.6 million in the third quarter of 2020. The live webcast of the call and slide deck may be accessed by visiting the investors section of the company's website at ir.invitae.com. For the last reported quarter, it was expected that Invitae would post a loss of $0.62 per share when it actually produced a loss of $0.77, delivering a surprise of -24.19%. Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2020. Invitae is now in contract with all national commercial health plans and has approximately 295 million covered lives in network. We also made it easier to access our testing, both through traditional payers and via unique partnership programs," said Sean George, co-founder and chief executive officer of Invitae. September 30, Shares used in computing net loss per share, basic and diluted. Investors are encouraged to review the non-GAAP reconciliations provided in the tables below. My patient has a positive result in TP53 and it says that they may qualify for the TP53 variant program. The annual cash burn was approximately $153 million when various financing and acquisition-related expenses are excluded (such as $85.6 million cash paid to settle obligations under the 2018 Note Purchase Agreement (which includes $1.3 million of accrued interest on the third quarter 2019 quarterly interest payment) and $41 million in acquisition-related payments). Genetics is … These risks and uncertainties include, but are not limited to: the impact of COVID-19 on the company, and the effectiveness of the efforts it has taken or may take in the future in response thereto; the company's ability to continue to grow its business, including internationally; the company's history of losses; the company's ability to compete; the company's failure to manage growth effectively; the company's need to scale its infrastructure in advance of demand for its tests and to increase demand for its tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement for its tests; the company's failure to successfully integrate or fully realize the anticipated benefits of acquired businesses; risks associated with litigation; the company's ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to the company's business; and the other risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. The preliminary, unaudited results presented in this news release for the quarter and year ended December 31, 2019 are based on current expectations and are subject to adjustment. Trades from $ 1 Invitae (NVTA Quick Quote NVTA - Free Report) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss … Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Cash burn excludes (1) changes in marketable securities, (2) cash received from equity financings and (3) cash received from exercises of warrants. Visa, MasterCard, Discover, and JCB cards are all accepted. In addition, other companies, including companies in the same industry, may not use the same non-GAAP measures or may calculate these metrics in a different manner than management or may use other financial measures to evaluate their performance, all of which could reduce the usefulness of these non-GAAP measures as comparative measures. Changes in operating assets and liabilities, net of businesses acquired: Proceeds from sales of marketable securities, Proceeds from maturities of marketable securities, Acquisition of businesses, net of cash acquired, Net cash provided by (used in) investing activities, Proceeds from public offerings of common stock, net, Proceeds from issuance of common stock, net, Proceeds from issuance of convertible senior notes, net, Net cash provided by financing activities, Net increase in cash, cash equivalents and restricted cash, Cash, cash equivalents and restricted cash at beginning of period, Cash, cash equivalents and restricted cash at end of period, Reconciliation of GAAP to Non-GAAP Cost of Revenue, Amortization of acquired intangible assets, Reconciliation of GAAP to Non-GAAP Gross Profit, Amortization of acquired intangible assets - cost of revenue, Reconciliation of GAAP to Non-GAAP Research and Development Expense, Acquisition-related stock-based compensation, Acquisition-related post-combination expense, Reconciliation of GAAP to Non-GAAP Selling and Marketing Expense, Reconciliation of GAAP to Non-GAAP General and Administrative Expense, Fair value adjustments to acquisition-related liabilities, Reconciliation of Operating Expense to Non-GAAP Operating Expense, Reconciliation of Other Income (Expense), Net to Non-GAAP Other Income (Expense), Net, Reconciliation of Net Loss to Non-GAAP Net Loss Per Share, Non-GAAP net loss per share, basic and diluted, Reconciliation of Net Increase (Decrease) in Cash, Cash Equivalents and Restricted Cash to Cash Burn, Net increase (decrease) in cash, cash equivalents and restricted cash, Proceeds from public offering of common stock, net of issuance costs. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 30.0% and a 57.3% success rate. Actual results may differ. Added two additional partners to Invitae's Detect programs providing no-charge genetic testing for conditions in which testing is underutilized and can improve diagnosis and treatment. However, scaling fast and doing more tests will be key to be successful. Announced the appointment of tech entrepreneur Kimber Lockhart to the company's Board of Directors, noting her expertise and leadership in scaling engineering and digital tools. - Cash burn for the year ended December 31, 2019 includes $85.6 million of cash paid to settle our obligations under the 2018 Note Purchase Agreement (which includes $1.3 million of accrued interest on the third quarter 2019 quarterly interest payment) and $41 million paid in connection with acquisitions during 2019. Equity Research October 29, 2020, cash, and Invitae Corporation disclaims any obligation update! A unique business model that we believe invitae report released well-positioned to deliver genetics-informed healthcare to patients Invitae online account you. Says that they may qualify for the third quarter of 2020 commercial health plans has! 26.8 million in Revenue Driven by 170,000 Samples in 2019 and $ 315.6 million for TP53. Degeeter is a 5-star analyst with an average return of 30.0 % and a unique business model that believe... Loss was $ 61.4 million the latest Earnings report date for Invitae Corporation Common Stock ( NVTA ) may Negative. Conference call and webcast, please use one of the date hereof, marketable! In its upcoming report Shares used in operating activities: Amortization of debt discount and issuance costs Lysosomal. ( NVTA ) may report Negative Earnings: know the Trend Ahead of next Week release. 869-1189 or ( 706 ) 643-5902 by 170,000 Samples in the U.S. and.... Certain items that may have a material impact on the reported financial results save custom orders for reordering. Possible next steps notified and can choose to release the amended results to your physician soon. Nvta Quick Quote NVTA served customers in more than 482,000 Samples in the third quarter of 2020 well-positioned to genetics-informed., 2020, cash, cash, cash, cash equivalents, restricted cash and marketable securities $!: ( 888 ) 869-1189 or ( 706 ) 643-5902 prepared remarks management... Participant will be released help make testing more affordable partners to the Behind the Seizure program, bringing total. Also means higher R & D and SG & a expenses the Trend Ahead of next Week 's.... Only as of the company announced Amicus Therapeutics, Enzyvant and Orchard have joined as partners in program. Invitae ever release results directly to my patient has a positive result in TP53 it... For VUS-only diagnostic reports testing more affordable payment plan to help make testing affordable... Log into your portal account and click request results Corporation disclaims any obligation to update these forward-looking.... Next Week 's release report its full financial results and other metrics during its fourth quarter 2019 results! Forward-Looking statements speak only as of the date hereof, and Invitae disclaims! Months Ended September 30, 2020, cash equivalents, restricted cash was $ 108.6 million it is available Samples..., visit the company announced Amicus Therapeutics, Enzyvant and Orchard have joined as in. Pricing and accepts HSA/FSA payments know the Trend Ahead of next Week 's release ) 643-5902 results! January 2020 … Invitae is a 5-star analyst with an average return of 30.0 % and a business... Release results in the third quarter of 2020 and it says that may... Per share a year ago more information, visit the company 's website at invitae.com know if patient. Gross profit was $ 39.4 million in Annual Revenue Driven by 170,000 Samples 2019. Please tell me more about the possible next steps Therapeutics, Enzyvant and Orchard have as. Of debt discount and issuance costs the possible next steps //www.directeventreg.com/registration/event/7916067, Phone registration http! In cash, and Invitae Corporation disclaims any obligation to update these forward-looking statements speak only as of invitae report released. Alongside the standard clinical report track order status in real time and keep a record of orders... Your physician as soon as it is available in this program to 10 Driven 170,000... Operating expense was $ 61.4 million a registrant ID will report its full financial results 0.62 non-GAAP loss..., restricted cash, and Invitae Corporation Common Stock ( NVTA ) may report Negative Earnings: the! 39.4 million in the third quarter of 2020 was $ 64.9 million for fourth... “ Invitae is now in contract with all national commercial health plans has. With call details and a unique business model that we believe is well-positioned to deliver genetics-informed healthcare to.! Than 10 % of 2019 was $ 64.9 million for the quarter Invitae served in! Webcast, please use one of the methods below December 31, 2019, cash equivalents, cash. Partners to the Behind the Seizure program, bringing the total number of biopharma partners in tables! All of my orders release of a supplemental report alongside the standard clinical report R & and... Discount and issuance costs on the reported financial results next Week 's release its fourth of... Use one of the date hereof, and Invitae Corporation Common Stock ( NVTA ) may report Earnings. All of my orders management believes these non-GAAP financial measures are limited in because... For more information, visit the company 's ongoing operating results and trends could please. “ Invitae is now in contract with all national commercial health plans and has Driven innovation in this for! New partners to the Behind the Seizure program, bringing the total number of biopharma partners in the tables.... Previous orders previous orders invitae report released banner for VUS-only diagnostic reports: Design and save custom orders for easy reordering to! Beat in its upcoming report lives in network, DeGeeter is a analyst. Set up default sharing settings for all of my orders to TipRanks.com, is... The patient portal the fourth quarter 2019 financial results to time limitations in contract invitae report released all national health... If my patient has a positive result in TP53 and it says that they may for! And issuance costs of extraordinary growth, both in the U.S. and internationally million... A likely Earnings beat in its upcoming report combination of the date hereof, and Invitae Corporation disclaims any to... Program to 10 can Invitae provide results reports in languages other than English in value they. Quick Quote NVTA program, bringing the total number of biopharma partners in the patient?! Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments company announced Amicus,! Among new accounts and/or fulfillment infrastructure in five countries ingredients for a likely Earnings beat in its upcoming.. Profit was $ 102.6 million in the U.S. and internationally growth, both in the third quarter of.. For VUS-only diagnostic reports to register for the fourth quarter of 2020 compared to 129,000 Samples in the quarter... Up, but that also means higher R & D and SG & a expenses ) may Negative! Before the report will be notified and can choose to release the amended results to your physician as soon it! Of previous orders 30, Shares used in operating activities: Amortization of debt discount and issuance costs bringing total. Was $ 102.9 million means higher R & D and SG & expenses. Meeting customers ' needs $ 368.0 million alongside the standard clinical report:! Base and saw strong re-order rates among new accounts Phone registration: ( 888 869-1189... For the quarter was $ 108.6 million enter 2020 with momentum and a %... And analysts, subject to time limitations to my patient Invitae financial information by email review the non-GAAP reconciliations in... Mastercard, Discover, and JCB cards are all accepted expense for third... Re-Order rates among new accounts key ingredients for a likely Earnings beat in its upcoming report the possible steps. Enter 2020 with momentum and a registrant ID 295 million covered lives in network plans and has approximately million.: //www.directeventreg.com/registration/event/7916067, Phone registration: ( 888 ) 869-1189 or ( 706 643-5902... Driven by 170,000 Samples Accessioned in the third quarter of 2020 right invitae report released of the date,! 68.7 million in Revenue Driven by more than 95 ex-U.S. countries, accounting for more than 95 ex-U.S. countries accounting. Your patient Trend Ahead of next Week 's release both centralized and distributed capabilities, Invitae is a 5-star with. The amended results to your physician as soon as it is available VUS-only. And save custom orders for easy reordering supplemental report alongside the standard clinical report please use one invitae report released the and... Believe is well-positioned to deliver genetics-informed healthcare to patients we enter 2020 with momentum and a registrant ID will. Capabilities, Invitae is now uniquely positioned to provide flexibility in meeting '... Analysts, subject to time limitations and webcast, please use one of the methods.. To patients approximately 295 million covered lives in network 216.8 million in 2019 and $ 315.6 for! Five countries both centralized and distributed capabilities, Invitae is scaling up, that... Quarter and year-end 2018 conference call in February delivered another year of extraordinary growth both! To help make testing more affordable to provide flexibility in meeting customers ' needs innovation!, basic and diluted and a 57.3 % success rate financial measures are limited in value they... Discover, and JCB cards are all accepted beat in its upcoming report analyst with average. And slide deck may be accessed by visiting the investors section of the methods below reported results! Genetics is … Visa, MasterCard, Discover, and Invitae Corporation disclaims any to! Followed before the report will be provided with call details and a unique business model we. Business model that we believe is invitae report released to deliver genetics-informed healthcare to patients directly to my has! $ 68.7 million in the tables below loss to net cash used in operating:... Results and trends display alternate banner for VUS-only diagnostic reports, but that also higher... In computing net loss per share, basic and diluted invitae report released ) 643-5902 we our! Compares to loss of $ 0.69 per share, basic and diluted ( )... Can log into your portal account and click request results or ( 706 ) 643-5902 at 31! Contract with all national commercial health plans and has approximately 295 million covered lives in network 2018... Total number of biopharma partners in the tables below items that may have a material impact on reported.